

Gastroenterology

Volume 170 / Issue 1

January 2026

www.gastrojournal.org

TABLE OF
CONTENTS

Contents

ON THE COVER



ESD vs TAMIS in Early Rectal Neoplasms. See article by de Frutos Rosa, et al, page 161 for additional information.

COMMENTARIES

- 1 **Integrated IBD Care in the Community: Evaluating Sustainable Models and Building a Framework for the Future**
E. R. Cohen, T. Ritter, and IBD Community Care Initiative Working Group

MENTORING, EDUCATION, AND TRAINING CORNER

- 6 **Abdominal Ultrasound Training for Gastroenterologists in Asia: Considerations and Sample Program**
S. Uchida-Kobayashi, W. C. Wing Chu, and N. Kawada

EDITORIALS

- 12 **New-Onset Diabetes: A Window Into Early Pancreatic Cancer Detection?**
S. S. Olesen and V. K. Singh
See Chari ST et al on page 106.
- 14 **For Early Rectal Neoplasms, the Time Has Come to Move Beyond the Transanal Minimally Invasive Surgery Era: Endoscopic Submucosal Dissection Is No Longer the Challenger—It Is the Standard to Beat**
J. Jacques and J. Steingrimsson
See de Frutos Rosa D et al on page 161.
- 16 **Foundation Models in Medicine, Gastroenterology, and Endoscopy: The Next Frontier?**
L. Rafiee Sevyeri and D. von Renteln
See Jong MR et al on page 174.

 Video

 Related article in CGH

 Hot Papers From New Investigators

 CME quiz

 Editorial accompanies this article

 Additional online content available

 Cover

Publisher: *Gastroenterology* (ISSN 0016-5085) is published monthly (semi-monthly in April) in two indexed volumes by Elsevier Inc., 1600 John F. Kennedy Boulevard, Suite 1600, Philadelphia, PA 1910, United States. Periodicals postage paid at New York, NY and additional mailing offices. POSTMASTER: Send address changes to Elsevier, Journal Returns, 450 Fame Avenue, Hanover, PA 17331, USA. 2026 US subscription rates: individual, \$848.00; student and resident, \$323.00. Outside of the U.S. and possessions: individual, \$1026.00; student and resident, \$596.00; surface delivery, no additional charge; air mail delivery, add \$78.00. Prices subject to change without notice.

18 How Should Endoscopists Approach Patients With Upper Gastrointestinal Bleeding and Persistent Hemodynamic Instability?

R. Pittayanon, A. A. Alali, and A. N. Barkun

See Obeidat M et al on page 199.

GASTRO CURBSIDE CONSULT

21 A Curious Culprit Behind Biliary Pus: What's the Diagnosis?

P. Pal, U. K. Marri, and D. N. Reddy

25 An Unusual Case of Fever and Biliary Dilatation in an Adult

J. Ye, Y. Gong, and C. Zhu

29 A Rare Case of Chronic Diarrhea

L. Liu, G. Chen, and D. Yuan

ELECTRONIC GASTRO CURBSIDE CONSULT

For a full list, please see the table of contents online at www.gastrojournal.org.

REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

34 Gastroenteropancreatic Neuroendocrine Tumors

N. Vijayvergia, L. S. Lee, and B. W. Katona

50 An Evidence-Based Practical Review on Common Benign Anorectal Disorders: Hemorrhoids, Anal Fissure, Dyssynergic Defecation, and Fecal Incontinence

A. E. Bharucha, C. H. Knowles, and A. Malcolm

ORIGINAL RESEARCH

Full Reports

GI Cancer

70 Chemical Perturbations Impacting Histone Acetylation Govern Colorectal Cancer Differentiation

P. Likasitwatanakul, Z. Li, P. Doan, S. Spisak, A. K. Raghawan, Q. Liu, P. Liow, S. Lee, D. Chen, P. Bala, P. Sahgal, D. Aitymbayev, J. S. Thalappillil, M. Papanastasiou, W. Hawkins, S. A. Carr, H. Park, J. M. Cleary, J. Qi, and N. S. Sethi

Targeting specific enzymes that coordinate epigenetic regulation can force colorectal cancer cells to mature into normal states, revealing a new therapeutic approach to reduce tumor plasticity and growth.

89 Selective Urokinase Inhibition Plus Chemotherapy: A Novel Approach to Pancreatic Cancer Treatment via Enhanced Antitumor Immunity and Decreased Metastasis

S. M. Zahid Hosen, A. A. Kumar, Z. Xu, A. R. Mekapogu, C. Perera, T. Pang, R. Pirola, J. Wilson, D. Goldstein, B. J. Buckley, M. J. Kelso, M. Ranson, and M. Apte

This study provides evidence for a new treatment targeting a specific molecule in the pancreatic cancer microenvironment that significantly reduces tumor growth and metastasis.

106 Risk of Pancreatic Cancer in Glycemically Defined New-Onset Diabetes: A Prospective Cohort Study

S. T. Chari, B. Wu, C. Lopez, E. Lustigova, Q. Chen, S. K. Van Den Eeden, A. D. Leimpeter, W. Fisher, A. Wood, A. S. Alexander, J. Valenta, S. S. Vege, E. E. Carlson, K. G. Rabe, P. A. Hart, L. Qian, Y.-Q. Zhao, N. Yusuf, L. Matrisian, B. Kenner, J. A. Rinaudo, A. Maitra, and Z. Feng

See editorial on page 12.

Patients with new onset of diabetes identified by reviewing current and past glucose values have a 0.5%–1% chance of being diagnosed with pancreatic cancer in the subsequent 3 years.

Inflammatory Bowel Disease

- 118** **Early Infliximab Levels and Clearance Predict Outcomes After Infliximab Rescue in Acute Severe Ulcerative Colitis: Results From PREDICT-UC**
C. F. D. Li Wai Suen, M. C. Choy, D. Con, K. Cheng, J. Nigro, K. Breheney, K. Boyd, R. Pena, K. Burrell, O. Rosella, D. Proud, R. Brouwer, A. Gorelik, D. Liew, W. R. Connell, E. K. Wright, K. M. Taylor, A. Pudipeddi, M. Sawers, B. Christensen, W. Ng, J. Begun, G. L. Radford-Smith, M. Garg, N. Martin, D. R. van Langenberg, N. S. Ding, L. Beswick, R. W. Leong, M. P. Sparrow, C. Grosserichter-Wagener, H. te Velhuis, K. Visvanathan, and P. De Cruz

In patients with a severe flare of ulcerative colitis, measuring infliximab level in the blood 3 days after infliximab rescue may predict which patients will fail infliximab or need bowel surgery.

Functional GI Disease

- 132** **Low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet Improves Colonic Barrier Function and Mast Cell Activation in Patients With Diarrhea-Predominant Irritable Bowel Syndrome: A Mechanistic Trial**
J. Gao, A. A. Lee, S. Abtahi, J. R. Turner, M. Grover, A. Schmidt, T. M. Schmidt, J. W. Nee, J. Iturrino, A. Lembo, W. D. Chey, J. W. Wiley, and P. Singh

A diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols strengthened the gut barrier and stabilized activated mast cells seen in patients with diarrhea-predominant inflammatory bowel disease via improving the gut microbiome and reducing lipopolysaccharide levels in the stool.

Hepatobiliary

- 148** **Enhancement of Inpatient Mortality Prognostication With Machine Learning in a Prospective Global Cohort of Patients With Cirrhosis With External Validation**
S. Silvey, P. S. Kamath, J. George, A. Choudhury, Q. Xie, M. Topazian, H. D. Mekonnen, Z. Cao, A. Nagral, K. R. Reddy, D. Adebayo, S. K. Asrani, N. Rajoriya, M. Arrese, S. Aghayeva, M. Sharma, S. G. Huezio, A. Gadano, H. B. Yapici, N. Debzi, J. Shaw, S. Albhaisi, J. L. Pérez Hernández, Y. Wang, F. Peng, L. Wei, C. E. Eapen, H. K. Tan, J. Y. Fung, R. Rajaram, K. Thanapirom, H. Adanör, A. Doyle, Shalimar, M. Su, D. Jothimani, Y. Cai, R. M. Velazquez, W. Wang, M. Gounder, C. Gofton, S. Barutcu, B. Haktaniyan, A. Q. Farias, A. D. Aravinthan, C. Bera, S. Singh, P. C. Hayes, R. Idilman, A. Torre, M. R. Alvares-da-Silva, W.-K. Seto, F. Wong, B. J. Bush, L. R. Thacker, N. Patel, and J. S. Bajaj, on behalf of CLEARED Investigators

A machine learning model was developed that improves prediction of inpatient death over traditional statistics across a global cirrhosis cohort, which was validated in a US-based national cirrhosis cohort.

Endoscopy

- 161** **A Randomized Trial of Endoscopic Submucosal Dissection vs Transanal Minimally Invasive Surgery in Early Rectal Neoplasms: DSETAMIS-2018 Study**
D. de Frutos Rosa, I. Alonso Sebastián, D. Barquero Declara, J. Badia Closa, Ó. Nogales, L. M. Jiménez Gómez, J. Santiago García, F. Valentín Gómez, A. Royuela Vicente, A. Sánchez Movilla, E. Albéniz, and A. Herreros de Tejada Echanojáuregui, on behalf of the Mucosal Resection and Third-Space Endoscopy Working Group from the Spanish Society of Gastrointestinal Endoscopy

See editorial on page 14.

Endoscopic submucosal dissection appears to be noninferior to transanal minimally invasive surgery in 12-month local recurrence rates of early rectal neoplasms, with shorter hospital stays, lower costs, and similar safety outcomes.

- 174** **GastroNet-5M: A Multicenter Dataset for Developing Foundation Models in Gastrointestinal Endoscopy**
M. R. Jong, T. G. W. Boers, K. N. Fockens, J. B. Jukema, C. H. J. Kusters, T. J. M. Jaspers, R. A. H. van Eijck van Heslinga, F. C. Slooter, M. R. Struyvenberg, R. Bisschops, J. A. van der Putten, P. H. N. de With, F. van der Sommen, A. J. de Groof, and J. J. G. H. M. Bergman, on behalf of the BONS-AI Consortium

See editorial on page 16.

GastroNet-5M is a publicly available dataset of 5 million endoscopic images that may improve the accuracy and efficiency of artificial intelligence systems in gastrointestinal endoscopy.

GI Bleeding**188 The Natural History of Gastroesophageal Varices in Children With Portal Hypertension***O. Ackermann, O. Bernard, S. Franchi-Abella, M. Almes, C. Tanase, E. Jacquemin, and M. Duché*

Varices in the esophagus and stomach that carry a high risk of bleeding are found in 40% of children with portal hypertension, and one-fourth of these cases are detected before the age of 12 months.

RESEARCH LETTERS**199 Hemodynamic Status as a Determinant Factor of Optimal Endoscopy Timing in Upper****Gastrointestinal Bleeding: Results From an International Survey of 533 Clinicians***M. Obeidat, D.-E. Floria, B. Teutsch, Z. Abonyi-Tóth, P. Hegyi, B. Eröss, and International Advisory Group of The Survey*

See editorial on page 18.

203 Global Discrepancies in Inflammatory Bowel Disease Care Reflect Health Care Expenditure Per Capita*C. N. Bernstein, R. Gearry, Z. Nugent, J. Witt, J. Burisch, G. G. Kaplan, and Global IBD Management Cascades Committee***CONTINUING MEDICAL EDUCATION (CME)/MOC ACTIVITIES****e14 CME Exam 1: Risk of Pancreatic Cancer in Glycemically Defined New-Onset Diabetes: A Prospective Cohort Study****e17 CME Exam 2: Enhancement of Inpatient Mortality Prognostication With Machine Learning in a Prospective Global Cohort of Patients With Cirrhosis With External Validation****GASTRO DIGEST****207 The Enteric Nervous System Tastes Your Food!***C. Y. Q. Lee and K. G. Margolis***208 Microbiota Transplantation — It's a Match and a Mismatch***D. Reed***208 Skipping Surgery in Rectal and Other Solid Cancers With Mismatch Repair Deficiency Using Immunotherapy***M. D. Giraldez***209 Impact of Behavioral Interventions on Fecal Immunochemical Testing Uptake From a Randomized Trial***N. Forbes***CORRESPONDENCE****211 Comments on Statistical and Mechanistic Aspects of Perforin and CXCL9 in IBD-Induced Depression***Y. Kong, X. Shen, K. Xue, and H. Wang***212 Reply***S. Huang, D. Tian, and D. Zhang***212 Concerns Regarding the Clinical Applicability and Statistical Analysis of TXI in the deTXIon Trial for Colorectal Lesion Detection***H. Tian and Y. Bian*

- 213 **Methodological Considerations for Further Enhancing the Clinical Impact of the deTXlon Study**
B. Yan and S. Chang
- 214 **TXI Raises Detection of Non-Neoplastic Polyps Without Improving Clinically Meaningful Neoplasia Endpoints**
Z. Li, J. Huang, and L. Xie
- 215 **Reply**
N. Toyoshima, T. Shibata, and Y. Saito
- 216 **Artificial Intelligence in Inflammatory Bowel Disease Management**
A. Shang, W. Wang, and K. Zhao
- 217 **Reply**
M. Iacucci, G. Santacroce, and S. Ghosh
- 218 **Comments on "Risk of Gastric Adenocarcinoma After Eradication of *Helicobacter pylori*"**
J. Ji, X. Shi, N. Luo, and L. Liang
- 219 **Correspondence on "Risk of Gastric Adenocarcinoma After Eradication of *Helicobacter pylori*"**
H. Xing, Y. Su, and L.-Y. Zhang
- 220 **Multi-Mechanistic Persistence of Gastric Cancer Risk Post-*Helicobacter pylori* and Surveillance Strategies**
Z. Shi, J. Jia, L. Shan, and C. Yang
- 221 **Clarifying Gastric Cancer Risk After *Helicobacter pylori* Eradication**
E. Kameoka, H. Saito, T. Hikichi, J. Nakamura, and H. Ohira
- 222 **Reply**
A.-K. Wiklund and J. Lagergren
- 223 **Critical Analysis of "Remodelling the Colon With Ileal Properties to Treat Short Bowel Syndrome"**
Z. Xu and L. Wang
- 223 **Reply**
T. Liu, R. A. Shivdasani, and X. Huang
- 224 **Reconsidering Genomic Stability in Esophageal Cancer Stem Cells: Insights From Chromothripsis**
X. Yu, W. Cai, and W. Wang
- 225 **Reply**
W. Xian, J. Ajani, and F. McKeon
- 226 **Comments on "Eradication Therapy to Prevent Gastric Cancer in *Helicobacter pylori*-Positive Individuals"**
Q. Xie, F. Zhang, and J. Wang
- 227 **Methodological Considerations in the Meta-Analysis on *Helicobacter pylori* Eradication for Gastric Cancer Prevention**
J. Chen and L. Yan

228 High Prevalence and Local Dissemination of Daptomycin-Resistance Mutations for *Enterococcus faecium* in Cirrhotic Patients

www

Z.-L. Deng, N. Safaei, S. L. Schütte, V. Ohlendorf, B. Maasoumy, and A. C. McHardy

231 Retraction Notice**Access to the full content of Gastroenterology Online is available to all subscribers!**

AGA members have seamless access to full *Gastroenterology* content from the AGA Web site. Simply sign in to <http://www.gastro.org>, visit the Publications section of the Web site, and click on *Gastroenterology*. You will be directed to the Journal Web site and will have full access to all content without having to supply a different username and password. Members can also visit <http://www.gastrojournal.org> directly and click on "Activate Online Access." Nonmember subscribers must create an online user account and activate their subscription to access the full text of articles on *Gastroenterology* Online. To activate your individual online subscription, please visit <http://www.gastrojournal.org> and click on "Activate Online Access." To activate your account, you

will need your subscriber account or member number, which you can find on your mailing label, (AGA members must use their 10-digit member number, including leading zeros). If you have any questions regarding your online subscription please call Elsevier Customer Service at (800) 654-2452.

Institutional access to *Gastroenterology* Online will be allowed only by limited site licensing. Further instructions will be available online. Personal subscriptions to *Gastroenterology* Online are for individual use only and may not be transferred. Use of *Gastroenterology* Online is subject to agreement to the terms and conditions of use as indicated online.

AGA Member Number**Your Account Number****Sample
mailing
label**

GAST0000101864

JANE DOE
531 MAIN ST.
CENTER CITY, NY 10001-0011GAST V91-4 1234567-8
JANE DOE
531 MAIN ST
CENTER CITY, NY 10001-001